Glenmark Pharmaceuticals U.S. > Dermatology > Results From A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Exploratory, Multicenter Study Of GBR 830 In Adult Patients With Moderate-To-Severe Atopic Dermatitis
Results From A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Exploratory, Multicenter Study Of GBR 830 In Adult Patients With Moderate-To-Severe Atopic Dermatitis
